AKT1 and ovarian carcinoma: Inhibition of the AKT/mTOR pathway by the dual inhibitors, GSK458, AZD2014 and BEZ235 reduced cell invasion and migration in thyroid, pancreatic, and ovarian cancer in preclinical models (43–46).